Kraig Biocraft Laboratories' Prepares for First Monster Silk(TM) Textiles
May 05 2014 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig"), the
leading developer of advanced spider silk based fibers, announced
today that Warwick Mills, Inc. ("Warwick"), a leader in the
engineering and development of advanced technical textiles and
protective materials, is preparing to weave the first textiles with
Kraig's Monster Silk™ recombinant spider silk. This is part of
Kraig's collaborative development initiative of advanced spider
silk based textiles.
Kraig previously shipped Monster Silk™ yarn to Warwick, which
after studying the material, requested that it be processed to
additional specifications. The material was shipped back to Kraig
and then studied by a silk spinning expert who analyzed the fibers.
The fibers were then processed according to the directions and
specifications of the spinning expert. Recently, Kraig
received the reprocessed Monster Silk™ and shipped the material to
Warwick. Warwick is now testing and analyzing Kraig's Monster
Silk™ recombinant spider silk and determining the best ply and cord
twisting for yarn optimization in preparation for creating sample
textiles.
"We appreciate and respect the fact that Warwick asked us to
reprocess the material instead of just moving forward at full speed
with weaving or knitting," said Kraig CEO and founder, Kim
Thompson. "Warwick has taken the time to do this right. As a
result, the development of Monster Silk™ based textiles is at an
exciting stage, Warwick is preparing to create the first Monster
Silk™ textiles."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully
reporting biotechnology company is the leading developer of
genetically engineered spider silk based fiber technologies. The
Company has achieved a series of scientific breakthroughs in the
area of spider silk technology with implications for the global
textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "if," "develops," "researching,"
"research," "pilot," "potential," "could" or other words or phrases
of similar import. Forward looking statements include descriptions
of the Company's business strategy, outlook, objectives, plans,
intentions and goals. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Sep 2023 to Sep 2024